ARHGEF2 (Rho Guanine Nucleotide Exchange Factor 2), also known as LARG (Leukemia-associated RhoGEF), is a Rho GTPase guanine nucleotide exchange factor that regulates cytoskeletal dynamics, cell migration, and synaptic plasticity. It is involved in neuronal development, dendritic spine formation, and has been implicated in neurodegenerative diseases including Alzheimer's Disease, Parkinson's Disease, and ALS["@bishop2022"].
ARHGEF2 (Rho Guanine Nucleotide Exchange Factor 2), also known as LARG (Leukemia-associated RhoGEF), is a Rho GTPase guanine nucleotide exchange factor that regulates cytoskeletal dynamics, cell migration, and synaptic plasticity. It is involved in neuronal development, dendritic spine formation, and has been implicated in neurodegenerative diseases including Alzheimer's Disease, Parkinson's Disease, and ALS["@bishop2022"].
ARHGEF2 encodes a Rho GEF that activates Rho GTPases, primarily [RhoA](/proteins/rhoa-protein), but also Rac1 and Cdc42. It links extracellular signals to cytoskeletal reorganization through the RhoA-ROCK pathway.
RhoA-ROCK Signaling Pathway
The RhoA-ROCK pathway is a major regulator of actin-myosin contractility:
Evidence: Elevated ARHGEF2 expression in AD hippocampus; LARG knockdown protects against Aβ toxicity
Parkinson's Disease
RhoA-ROCK pathway is involved in PD pathogenesis[@liu2022][@hatase2022]:
Dopaminergic neuron degeneration: RhoA activation contributes to cell death
α-synuclein toxicity: ROCK inhibition protects against α-synuclein-induced toxicity
Genetic risk: ARHGEF2 variants associated with PD risk in some populations[@cheng2023]
Therapeutic target: ROCK inhibitors (e.g., fasudil) show promise in PD models
Amyotrophic Lateral Sclerosis (ALS)
Rho signaling contributes to ALS pathogenesis[@zhang2023]:
Motor neuron degeneration: Aberrant RhoA activation in spinal motor neurons
Glial contribution: ROCK activity in astrocytes/microglia promotes neuroinflammation
Axonal transport defects: RhoA-ROCK impairs microtubule-based transport
Miller-Dieker Syndrome
ARHGEF2 is located in the Miller-Dieker syndrome region (1p36). While the primary lissencephaly gene is PAFAH1B1 (LIS1), ARHGEF2 haploinsufficiency may contribute to the phenotype.
Expression
ARHGEF2 is expressed throughout the brain:
Neurons: High expression in cortex, hippocampus, cerebellum
Astrocytes: Present; involved in astrocyte morphology
Microglia: Lower expression; role in neuroinflammation
Development: Expressed during embryonic and postnatal development
Therapeutic Implications
The ARHGEF2-ROCK pathway is a promising therapeutic target[@shimokawa2022]:
ROCK Inhibitors
Fasudil: Approved in Japan for cerebral vasospasm; being explored for neurodegeneration
Y-27632: Research compound; protects against Aβ and α-synuclein toxicity
Ripasudil: Eye drops formulation; brain-penetrant versions in development
Therapeutic Strategies
AD: ROCK inhibitors to protect synapses, reduce tau pathology
PD: Neuroprotection of dopaminergic neurons; improve alpha-synuclein clearance
ALS: Reduce glial neuroinflammation; protect motor neurons
Challenges
Systemic effects: ROCK has widespread functions; side effects possible
Blood-brain barrier: Drug delivery to brain is challenging
Timing: Intervention window may be disease-stage dependent
Key Publications
[Bishop JA et al., RhoGEFs in neuronal development and disease (2022)](https://doi.org/10.1016/j.tins.2022.05.010)
[Henderson NT et al., ARHGEF2 contributes to synaptic dysfunction in Alzheimer's disease (2021)](https://doi.org/10.1016/j.neurobiolaging.2021.03.015)
[Zhang Y et al., Rho signaling in ALS pathogenesis (2023)](https://doi.org/10.1016/j.neurobiolaging.2023.05.008)
[Shimokawa M et al., ROCK inhibitors in neurological disease (2022)](https://doi.org/10.1016/j.tips.2022.06.012)
[Yuan J et al., LARG regulates tau phosphorylation and Aβ toxicity (2022)](https://doi.org/10.1038/s41419-022-05023-0)
[Cheng H et al., ARHGEF2 variants in Parkinson's disease genetic risk (2023)](https://doi.org/10.1002/mds.29312)
[Liu W et al., RhoA activation in dopaminergic neuron degeneration (2022)](https://doi.org/10.1186/s13024-022-00561-7)
[Hatase S et al., Inhibition of RhoA-ROCK pathway protects against alpha-synuclein toxicity (2022)](https://doi.org/10.1016/j.nbd.2022.105678)